Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.

Cancer science - 1 Jun 2008

Manshouri Taghi, Quintás-Cardama Alfonso, Nussenzveig Roberto H, Gaikwad Amos, Estrov Zeev, Prchal Josef, Cortes Jorge E, Kantarjian Hagop M, Verstovsek Srdan

Abstract excerpt

The somatic activating janus kinase 2 mutation (JAK2)(V617F) is detectable in most patients with polycythemia vera (PV). Here we report that CP-690,550 exerts greater antiproliferative and pro-apoptotic activity against cells harboring JAK2(V617F) compared with JAK2(WT). CP-690,550 treatment of murine factor-dependent cell Patersen-erythropoietin receptor (FDCP-EpoR) cells harboring human wild-type or V617F JAK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythroid Precursor Cells
Share to Erythropoietin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Potential, Mitochondrial

Share to Piperidines

Share to Polycythemia Vera

Share to Pyrroles

Share to Receptors, Erythropoietin

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 18482053
DOI: 10.1111/j.1349-7006.2008.00817.x
PMCID: PMC4829954

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.PMID 18482053Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.Semantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.Semantic proximity Read ↗

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.Semantic proximity Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

JAKing up hematopoietic proliferation.Semantic proximity Read ↗

Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthSemantic proximity Read ↗

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.Semantic proximity Read ↗

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.Semantic proximity Read ↗

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Semantic proximity Read ↗

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.